Argenx Se (ARGX) Operating Income (2016 - 2026)
Argenx Se's (ARGX) quarterly Operating Income came in at $493.0 million in Q2 2026, up 145.2% on a YoY basis from $201.1 million in Q2 2025, and up 25.13% quarter-over-quarter from $394.0 million in Q1 2026.
Analysis
Argenx Se (ARGX) Operating Income (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Operating Income for 11 consecutive years, with $493.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Operating Income rose 145.2% year-over-year to $493.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.6 billion (up 250.06% YoY), and the FY2025 full-year result was $1.1 billion, up 4966.57% from the prior year.
- Operating Income improved to $493.0 million in Q2 2026 per ARGX's latest filing, from $394.0 million in the prior quarter.
- Across five years, Operating Income topped out at $493.0 million in Q2 2026 and bottomed at -$222.7 million in Q1 2022.
- Historically, Operating Income has averaged $57.4 million across 5 years, with a median of -$15.6 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Operating Income slumped 1713176.92% in 2022, then surged 2340.22% in 2025.
- Over 5 years, Operating Income stood at -$114.4 million in 2022, then dropped by 21.14% to -$138.6 million in 2023, then soared by 174.33% to $103.0 million in 2024, then jumped by 256.76% to $367.6 million in 2025, then surged by 34.11% to $493.0 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered $493.0 million, $394.0 million, and $367.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -1.55 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -1.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 493.00 Mn |
| Mar 31, 2026 | 394.00 Mn |
| Dec 31, 2025 | 367.61 Mn |
| Sep 30, 2025 | 346.19 Mn |
| Jun 30, 2025 | 201.06 Mn |
| Mar 31, 2025 | 139.00 Mn |
| Dec 31, 2024 | 103.04 Mn |
| Sep 30, 2024 | 14.19 Mn |
| Jun 30, 2024 | -45.46 Mn |
| Mar 31, 2024 | -93.42 Mn |
| Dec 31, 2023 | -138.62 Mn |
| Sep 30, 2023 | -80.59 Mn |
| Jun 30, 2023 | -102.09 Mn |
| Mar 31, 2023 | -103.74 Mn |
| Dec 31, 2022 | -114.43 Mn |
| Sep 30, 2022 | -208.64 Mn |
| Jun 30, 2022 | 85.18 Mn |
| Mar 31, 2022 | -222.73 Mn |
| Dec 31, 2021 | -230.91 Mn |
| Sep 30, 2021 | 7.11 Mn |